Adolescents' Non-suicidal Behavior and Perception of Parents' Negative Emotional Expression and Family Communication

March 12, 2024 updated by: Wei XIA, PhD, Sun Yat-sen University

Relationship Between Non-suicidal Self-injury Behaviors in Adolescents and Young Adults and Perceived Parental Negative Emotional Expression and Family Communication Styles in Children:A Case-control Study

The starting point of this project is to study young people and adolescents, aiming to explore the correlation between non-suicidal behavior of young people and adolescents and the negative emotional expression of their parents and family communication. The purpose of this project is to investigate the non-suicidal self-injury behavior of teenagers aged 15-25 years by issuing questionnaires (sample size: 327 people). In order to find out whether there is any connection between family communication and non-suicidal self-injury behavior of young people and adolescents.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The incidence of non-suicidal self-injury（NSSI） among adolescents has obviously increased, which should attract the attention of the whole society. Their mental health problems will not only lead to personal pain and family burden, but also bring potential negative effects to future social development. Therefore, it is necessary to study the psychological problems of teenagers and their influencing factors. This study will conduct a case-control study from the perspective of family, and analyze the negative emotional expression and family communication style of parents of non-suicidal teenagers and their influence on non-suicidal self-injury behavior. This study is conducted in the form of scale, which will use the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI）、the Adolescent parent-child relationship intimacy questionnaire and the Ottawa Self-injury Inventory（OSI）.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
324

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The group of adolescents and young adults diagnosed as NSSI, and the control group includes adolescents and young adults with other mental diseases other than NSSI, healthy adolescents and young adults.

Description

1.Case group: NSSI patient group:

Inclusion Criteria:

  1. Patients who meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI;
  2. Age range: 15-25 years old;
  3. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;

Exclusion Criteria:

  1. Users with organic diseases and psychoactive substances;
  2. NSSI； caused by autism, TIC disorder, mental retardation and other emotional instability and bad mood;
  3. Religious self-injury or customary self-injury;
  4. Patients with schizophrenia, schizoaffective disorder, alcohol dependence, organic mental disorder and other mental disorders have been previously diagnosed.

2.Control group 1: Non-NSSI patients

Inclusion criteria:

  1. Psychiatric outpatients or inpatients can read and understand the contents of the questionnaire;
  2. Patients who do not meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI.
  3. Age range: 15-25 years old;
  4. Patients and/or guardians can give informed consent and participate in this study.

Exclusion criteria:

  1. Patients whose illness causes them unable to communicate or fill out questionnaires;
  2. Non-serious mental diseases, such as schizophrenia and schizoaffective disorder.

3.Control group 2: Healthy group

Inclusion criteria

  1. No mental illness;
  2. Age range: 15-25 years old;
  3. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;
  4. Patients and/or guardians can give informed consent and participate in this study.

Exclusion criteria

(1) Young people and adolescents who are unable to communicate or fill out questionnaires due to various organic reasons.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Case group: NSSI patient group
  1. Patients who meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI;
  2. Age range: 15-25 years old;
  3. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;
Other: Questionnaires set 1
Participants of case group will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI）、the Adolescent parent-child relationship intimacy questionnaire and the Ottawa Self-injury Inventory（OSI）.
Control group 1: non-NSSI patients
  1. psychiatric outpatients or inpatients can read and understand the contents of the questionnaire;
  2. Patients who do not meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI.
  3. Age range: 15-25 years old;
  4. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;
Other: Questionnaires set 2
Participants of control group 1 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
Control group 2: healthy group
  1. No mental illness;
  2. Age range: 15-25 years old;
  3. Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;
Other: Questionnaires set 3
Participants of control group 2 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Non-suicidal self-injury behavior of young people and adolescents
Time Frame: Baseline
There are 28 items in the Ottawa Self-injury Inventory, which are used to evaluate the frequency of NSSI and suicide in the last 1, 6 and 12 months, the age of first onset, the source and concealment of self-injury ideas, and the feeling of self-injury impulse.
Baseline
Expression of negative emotions of parents
Time Frame: Baseline
There are 40 items in the Parental Emotional Expression Questionnaire, which is used to measure parents' negative emotions. The scale adopts system, and the higher the dimension score, the greater the possibility of negative emotions.
Baseline
Parent-Adolescent communication scale
Time Frame: Baseline
There are 40 items in the parent-Adolescent communication scale, which is used to measure parent-child communication. The scale adopts Likert 5-point system, and the higher the score, the better the parent-child communication.
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Childhood Trauma Questionnaire
Time Frame: Baseline
There are 28 items in the Childhood Trauma Scale, which are used to measure childhood traumatic experiences. The scale adopts Likert 5-point system, and the higher the score, the more serious the childhood trauma experience.
Baseline
Parental Bongding Instrument
Time Frame: Baseline
There are 23 items in the Parenting Style Scale, which is used to measure the parenting style. The scale adopts Likert 4-point system, which consists of three factors: caring, encouraging autonomy and controlling.
Baseline
The parent-child relationship intimacy scale
Time Frame: Baseline
There are 29 items in the parent-child relationship intimacy scale, which are used to measure the parent-child relationship. The scale adopts Likert 5-point system, and the higher the score, the higher the intimacy of parent-child relationship.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Sun Yat-sen University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Wei Xia, PhD, Sun Yat-sen University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 31, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 26, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 4, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 13, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 12, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 202301

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings